drugset / Trial / NCT03780010
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
Phase 1
Completed
15 enrolled
Tracon Pharmaceuticals Inc.
University of Alabama at Birmingham · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, open-label, nonrandomized, phase 1b, dose-finding study of TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.
Timeline
- Start
- 2015-09
- Primary completion
- 2019-06
- Completion
- 2019-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carotuximab | Monoclonal antibody | — | — |
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |